in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Hovione signs agreement with Ligand Pharmaceuticals for Captisol technology
9:53 AM MDT | April 5, 2013 | Deepti Ramesh
Active pharmaceutical ingredients (APIs) producer Hovione (Loures, Portugal) says it has entered into a copromotion and collaboration agreement with Ligand Pharmaceuticals (La Jolla, CA) to provide Hovione’s customers access to Captisol technology. Captisol is a patent-protected, chemically modified cyclodextrin whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability, and dosing of APIs. Captisol is currently used in six marketed products. Hovione offers...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee